Episode 114 - Martijn Negen - COO of VarmX

from The BioHub: The Top Voices in Biotech · host Max Brennan - Biotech HeadHunter

We're joined by Martijn for an engaging discussion on VarmX's latest milestones & the wider biotech market.In Q4 2025, VarmX signed a strategic collaboration with CSL to fully fund a global ph3 trial & pre-launch readiness for their lead asset VMX-C001 - a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs. Martijn shares insight on how the deal came about, what it could mean for patients and VarmX in future, and why CSL are the right partner to develop & deliver VMX-C001 globally.

Episode metadata supplied by the publisher feed · Published Feb 9, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Episode 114 - Martijn Negen - COO of VarmX

0:00 35:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The BioHub: The Top Voices in Biotech?

This episode is 35 minutes long.

When was this The BioHub: The Top Voices in Biotech episode published?

This episode was published on February 9, 2026.

Can I download this The BioHub: The Top Voices in Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!